MX2010001630A - Amidas bicíclicas para mejorar las respuestas sinápticas glutamatergícas. - Google Patents
Amidas bicíclicas para mejorar las respuestas sinápticas glutamatergícas.Info
- Publication number
- MX2010001630A MX2010001630A MX2010001630A MX2010001630A MX2010001630A MX 2010001630 A MX2010001630 A MX 2010001630A MX 2010001630 A MX2010001630 A MX 2010001630A MX 2010001630 A MX2010001630 A MX 2010001630A MX 2010001630 A MX2010001630 A MX 2010001630A
- Authority
- MX
- Mexico
- Prior art keywords
- syndrome
- disorders
- treatment
- sleep apnea
- compounds
- Prior art date
Links
- -1 Bicyclic amides Chemical class 0.000 title abstract 2
- 230000002708 enhancing effect Effects 0.000 title 1
- 230000000848 glutamatergic effect Effects 0.000 title 1
- 230000009782 synaptic response Effects 0.000 title 1
- 210000004556 brain Anatomy 0.000 abstract 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 3
- 208000035475 disorder Diseases 0.000 abstract 3
- 230000029058 respiratory gaseous exchange Effects 0.000 abstract 3
- 208000003417 Central Sleep Apnea Diseases 0.000 abstract 2
- 208000019022 Mood disease Diseases 0.000 abstract 2
- 208000004756 Respiratory Insufficiency Diseases 0.000 abstract 2
- 206010038678 Respiratory depression Diseases 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 2
- 238000000034 method Methods 0.000 abstract 2
- 208000006096 Attention Deficit Disorder with Hyperactivity Diseases 0.000 abstract 1
- 208000036864 Attention deficit/hyperactivity disease Diseases 0.000 abstract 1
- 206010010356 Congenital anomaly Diseases 0.000 abstract 1
- 206010012289 Dementia Diseases 0.000 abstract 1
- 206010013647 Drowning Diseases 0.000 abstract 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 abstract 1
- 206010021133 Hypoventilation Diseases 0.000 abstract 1
- 108010025020 Nerve Growth Factor Proteins 0.000 abstract 1
- 102000007072 Nerve Growth Factors Human genes 0.000 abstract 1
- 208000004166 Obesity Hypoventilation Syndrome Diseases 0.000 abstract 1
- 208000018737 Parkinson disease Diseases 0.000 abstract 1
- 206010035004 Pickwickian syndrome Diseases 0.000 abstract 1
- 201000010769 Prader-Willi syndrome Diseases 0.000 abstract 1
- 208000006289 Rett Syndrome Diseases 0.000 abstract 1
- 208000034972 Sudden Infant Death Diseases 0.000 abstract 1
- 206010042440 Sudden infant death syndrome Diseases 0.000 abstract 1
- 208000030886 Traumatic Brain injury Diseases 0.000 abstract 1
- 230000003444 anaesthetic effect Effects 0.000 abstract 1
- 208000015802 attention deficit-hyperactivity disease Diseases 0.000 abstract 1
- 229940125717 barbiturate Drugs 0.000 abstract 1
- HNYOPLTXPVRDBG-UHFFFAOYSA-N barbituric acid Chemical compound O=C1CC(=O)NC(=O)N1 HNYOPLTXPVRDBG-UHFFFAOYSA-N 0.000 abstract 1
- 230000006399 behavior Effects 0.000 abstract 1
- 230000002490 cerebral effect Effects 0.000 abstract 1
- 230000003930 cognitive ability Effects 0.000 abstract 1
- 230000007812 deficiency Effects 0.000 abstract 1
- 206010027175 memory impairment Diseases 0.000 abstract 1
- 210000005036 nerve Anatomy 0.000 abstract 1
- 230000001537 neural effect Effects 0.000 abstract 1
- 239000003900 neurotrophic factor Substances 0.000 abstract 1
- 208000001797 obstructive sleep apnea Diseases 0.000 abstract 1
- 229940127240 opiate Drugs 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 201000000980 schizophrenia Diseases 0.000 abstract 1
- 201000002859 sleep apnea Diseases 0.000 abstract 1
- 208000020431 spinal cord injury Diseases 0.000 abstract 1
- 210000000225 synapse Anatomy 0.000 abstract 1
- 208000011580 syndromic disease Diseases 0.000 abstract 1
- 239000003053 toxin Substances 0.000 abstract 1
- 231100000765 toxin Toxicity 0.000 abstract 1
- 230000009529 traumatic brain injury Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4245—Oxadiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/52—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring condensed with a ring other than six-membered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
- C07D451/02—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
- C07D451/02—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
- C07D451/04—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof with hetero atoms directly attached in position 3 of the 8-azabicyclo [3.2.1] octane or in position 7 of the 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
- C07D451/02—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
- C07D451/04—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof with hetero atoms directly attached in position 3 of the 8-azabicyclo [3.2.1] octane or in position 7 of the 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring system
- C07D451/06—Oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
- C07D453/06—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing isoquinuclidine ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/08—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/08—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/08—Bridged systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- General Chemical & Material Sciences (AREA)
- Psychiatry (AREA)
- Psychology (AREA)
- Emergency Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Pulmonology (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Hydrogenated Pyridines (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US96436207P | 2007-08-10 | 2007-08-10 | |
| PCT/US2008/009508 WO2009023126A2 (en) | 2007-08-10 | 2008-08-08 | Bicyclic amides for enhancing glutamatergic synaptic responses |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2010001630A true MX2010001630A (es) | 2010-03-15 |
Family
ID=40351347
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2010001630A MX2010001630A (es) | 2007-08-10 | 2008-08-08 | Amidas bicíclicas para mejorar las respuestas sinápticas glutamatergícas. |
| MX2010001631A MX2010001631A (es) | 2007-08-10 | 2008-08-08 | Amidas biciclicas para mejorar las respuestas sinapticas glutamatergicas. |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2010001631A MX2010001631A (es) | 2007-08-10 | 2008-08-08 | Amidas biciclicas para mejorar las respuestas sinapticas glutamatergicas. |
Country Status (15)
| Country | Link |
|---|---|
| US (3) | US8263591B2 (enExample) |
| EP (1) | EP2187888B1 (enExample) |
| JP (2) | JP5576277B2 (enExample) |
| KR (2) | KR20100051678A (enExample) |
| CN (2) | CN101896183B (enExample) |
| AU (2) | AU2008287445A1 (enExample) |
| BR (2) | BRPI0814149A2 (enExample) |
| CA (2) | CA2702292A1 (enExample) |
| ES (1) | ES2560095T3 (enExample) |
| MX (2) | MX2010001630A (enExample) |
| NZ (1) | NZ583823A (enExample) |
| RU (2) | RU2010106975A (enExample) |
| SG (1) | SG163526A1 (enExample) |
| WO (1) | WO2009023126A2 (enExample) |
| ZA (1) | ZA201001691B (enExample) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101616592B (zh) | 2007-01-03 | 2013-06-05 | 瑟维尔实验室 | 用于提高谷氨酸能突触响应的3-取代的-[1,2,3]-苯并三嗪酮化合物 |
| TW200911768A (en) | 2007-05-17 | 2009-03-16 | Cortex Pharma Inc | Di-substituted amides for enhancing glutamatergic synaptic responses |
| US8168632B2 (en) | 2007-08-10 | 2012-05-01 | Cortex Pharmaceuticals, Inc. | Bicyclic amide derivatives for the treatment of respiratory disorders |
| US8263591B2 (en) | 2007-08-10 | 2012-09-11 | Cortex Pharmaceuticals, Inc. | Bicyclic amides for enhancing glutamatergic synaptic responses |
| WO2010087981A2 (en) * | 2009-02-02 | 2010-08-05 | Cortex Pharmaceuticals, Inc. | Bicyclic amide derivatives for enhancing glutamatergic synaptic responses |
| US9440982B2 (en) | 2012-02-07 | 2016-09-13 | Eolas Therapeutics, Inc. | Substituted prolines/piperidines as orexin receptor antagonists |
| NZ628491A (en) * | 2012-02-07 | 2016-06-24 | Eolas Therapeutics Inc | Substituted prolines / piperidines as orexin receptor antagonists |
| JP6663909B2 (ja) | 2014-08-13 | 2020-03-13 | エオラス セラピューティクス， インコーポレイテッド | オレキシンレセプターモジュレーターとしてのジフルオロピロリジン |
| US9739787B2 (en) | 2015-09-01 | 2017-08-22 | Abdulmohsen Ebrahim Alterki | Method for diagnosing sleep apnea by measuring adipsin and betatrophin levels |
| SI3414241T1 (sl) | 2016-02-12 | 2022-10-28 | Astrazeneca Ab | Halo-substituitani piperidini kot modulatorji receptorja oreksina |
| WO2018009256A1 (en) * | 2016-03-29 | 2018-01-11 | Respirerx Pharmaceuticals, Inc. | Compositions and methods for treating attention deficit disorders |
| JP2022534704A (ja) | 2019-06-04 | 2022-08-03 | ヘイガー バイオサイエンシズ，エルエルシー | オレキシンアンタゴニストとしてのイミダゾロ誘導体、組成物、及び方法 |
Family Cites Families (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3723436A (en) * | 1971-02-25 | 1973-03-27 | Sun Oil Co | Process for aromatic lactams |
| FR2597103B1 (fr) * | 1986-04-15 | 1988-12-16 | Provesan Sa | Procede de preparation de derives d'oxazinobenzothiazine 6,6-dioxyde |
| DK1156043T3 (da) * | 1992-07-24 | 2004-03-01 | Univ California | Lægemidler, der forøger synaptiske reaktioner formidlet af ampa-receptorer |
| US20020099050A1 (en) | 1993-07-23 | 2002-07-25 | Lynch Gary S. | Drugs that enhance synaptic responses mediated by AMPA receptors |
| US5650409A (en) * | 1995-06-02 | 1997-07-22 | Cortex Pharmaceuticals, Inc. | Benzoyl piperidines/pyrrolidines for enhancing synaptic response |
| US5736543A (en) * | 1996-04-03 | 1998-04-07 | The Regents Of The University Of California | Benzoxazines for enhancing synaptic response |
| WO1998011892A1 (en) * | 1996-09-17 | 1998-03-26 | The Regents Of The University Of California | Positive ampa receptor modulation to enhance brain neurotrophic factor expression |
| US6110935A (en) * | 1997-02-13 | 2000-08-29 | The Regents Of The University Of California | Benzofurazan compounds for enhancing glutamatergic synaptic responses |
| ES2258825T3 (es) | 1997-10-27 | 2006-09-01 | Cortex Pharmaceuticals, Inc. | Tratamiento de la esquizofrenia con ampakinas y neurolepticos. |
| US5985871A (en) | 1997-12-24 | 1999-11-16 | Cortex Pharmaceuticals, Inc. | Benzoxazine compounds for enhancing synaptic response |
| IL137720A0 (en) | 1998-02-18 | 2001-10-31 | Neurosearch As | Compounds and their use as positive ampa receptor modulators |
| US6713474B2 (en) | 1998-09-18 | 2004-03-30 | Abbott Gmbh & Co. Kg | Pyrrolopyrimidines as therapeutic agents |
| US6303542B1 (en) * | 2000-08-18 | 2001-10-16 | Rohm And Haas Company | Herbicidal 3-substituted-phenyl-1,2,3-benzotriazin-4-ones |
| PA8535601A1 (es) * | 2000-12-21 | 2002-11-28 | Pfizer | Derivados benzimidazol y piridilimidazol como ligandos para gabaa |
| AUPS255202A0 (en) | 2002-05-27 | 2002-06-13 | Monash University | Agents and methods for the treatment of disorders associated with motor neuron degeneration |
| JP2006522750A (ja) | 2003-04-11 | 2006-10-05 | ノボ ノルディスク アクティーゼルスカブ | 代謝性症候群ならびに関連の疾患および障害を治療するために、１１β−ヒドロキシステロイドデヒドロゲナーゼ１型阻害剤および抗高血圧剤を使用する併用療法 |
| US20050085446A1 (en) | 2003-04-14 | 2005-04-21 | Babu M.K. M. | Fluoroquinolone formulations and methods of making and using the same |
| GB0317482D0 (en) * | 2003-07-25 | 2003-08-27 | Pfizer Ltd | Nicotinamide derivatives useful as pde4 inhibitors |
| CN1897950A (zh) * | 2003-10-14 | 2007-01-17 | 惠氏公司 | 稠合芳基和杂芳基衍生物及其使用方法 |
| EP2061471A4 (en) | 2006-08-31 | 2012-02-01 | Univ Alberta | PROCESS FOR INHIBITING RESTRICTED DEPRESSION WITH POSITIVE ALLOSTER AMPA RECEPTOR MODULATORS |
| EP2114158B1 (en) * | 2007-01-03 | 2012-08-08 | Cortex Pharmaceuticals, Inc. | 3-substituted-[1,2,3]benzotriazinone compounds for enhancing glutamatergic synaptic responses |
| CN101616592B (zh) | 2007-01-03 | 2013-06-05 | 瑟维尔实验室 | 用于提高谷氨酸能突触响应的3-取代的-[1,2,3]-苯并三嗪酮化合物 |
| TW200911768A (en) * | 2007-05-17 | 2009-03-16 | Cortex Pharma Inc | Di-substituted amides for enhancing glutamatergic synaptic responses |
| US8263591B2 (en) | 2007-08-10 | 2012-09-11 | Cortex Pharmaceuticals, Inc. | Bicyclic amides for enhancing glutamatergic synaptic responses |
| EP2195303A4 (en) | 2007-09-20 | 2011-07-20 | Cortex Pharma Inc | 3-SUBSTITUTED 1,2,3-TRIAZIN-4-ONE AND 3-SUBSTITUTED 1,3-PYRIMIDIONE FOR INCREASING GLUTAMATERGIC SYNAPTIC REACTIONS |
-
2008
- 2008-08-08 US US12/733,073 patent/US8263591B2/en not_active Expired - Fee Related
- 2008-08-08 SG SG201004604-3A patent/SG163526A1/en unknown
- 2008-08-08 KR KR1020107004015A patent/KR20100051678A/ko not_active Ceased
- 2008-08-08 EP EP08795126.5A patent/EP2187888B1/en active Active
- 2008-08-08 ES ES08795126.5T patent/ES2560095T3/es active Active
- 2008-08-08 AU AU2008287445A patent/AU2008287445A1/en not_active Abandoned
- 2008-08-08 WO PCT/US2008/009508 patent/WO2009023126A2/en not_active Ceased
- 2008-08-08 RU RU2010106975/04A patent/RU2010106975A/ru not_active Application Discontinuation
- 2008-08-08 KR KR1020107005366A patent/KR20100045507A/ko not_active Withdrawn
- 2008-08-08 NZ NZ583823A patent/NZ583823A/en not_active IP Right Cessation
- 2008-08-08 CN CN2008801025333A patent/CN101896183B/zh not_active Expired - Fee Related
- 2008-08-08 CA CA2702292A patent/CA2702292A1/en not_active Abandoned
- 2008-08-08 MX MX2010001630A patent/MX2010001630A/es unknown
- 2008-08-08 CN CN201010207140A patent/CN101862330A/zh active Pending
- 2008-08-08 BR BRPI0814149-5A patent/BRPI0814149A2/pt not_active IP Right Cessation
- 2008-08-08 BR BRPI0823262-8A2A patent/BRPI0823262A2/pt not_active Application Discontinuation
- 2008-08-08 MX MX2010001631A patent/MX2010001631A/es active IP Right Grant
- 2008-08-08 CA CA2695742A patent/CA2695742C/en not_active Expired - Fee Related
- 2008-08-08 JP JP2010520992A patent/JP5576277B2/ja not_active Expired - Fee Related
-
2010
- 2010-02-17 AU AU2010200563A patent/AU2010200563A1/en not_active Abandoned
- 2010-03-04 RU RU2010107795/15A patent/RU2010107795A/ru not_active Application Discontinuation
- 2010-03-09 ZA ZA2010/01691A patent/ZA201001691B/en unknown
- 2010-04-21 JP JP2010098175A patent/JP2010215630A/ja active Pending
- 2010-09-03 US US12/807,379 patent/US8110584B2/en not_active Expired - Fee Related
-
2012
- 2012-07-25 US US13/557,681 patent/US9492440B2/en not_active Expired - Fee Related
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2009012430A (es) | Amidas disustituidas para mejorar las respuestas sinapticas glutamatergicas. | |
| SG163526A1 (en) | Bicyclic amides for enhancing glutamatergic synaptic responses | |
| MX2010002890A (es) | 1, 2, 3-triacin -4-onas sustituidas en la posicion 3 y 1, 3- pirimidinonas sustituidas en la posicion 3 para mejorar las respuestas sinapticas glutamatergicas. | |
| de la Hoz-Aizpurua et al. | Sleep bruxism. Conceptual review and update | |
| MX2009004071A (es) | Moduladores de bifenilsulfonilo y fenil-heteroarilsulfonilo del receptor de histamina h3 utiles para el tratamiento de trastornos relacionados con los mismos. | |
| Askenasy | Sleep disturbances in Parkinsonism | |
| UA88719C2 (ru) | Антагонисты рецепторов гистамина-3 | |
| WO2005079802A8 (en) | Bipyridyl amides as modulators of metabotropic glutamate receptor-5 | |
| WO2007105053A3 (en) | Tetralines antagonists of the h-3 receptor | |
| JOP20220102A1 (ar) | مثبطات المُسْتقبلة الأدرينِية adrac2 | |
| TN2009000278A1 (en) | 3-substituted-[1,2,3] benzotriazinone compounds for enhancing glutamatergic synaptic responses | |
| ATE457985T1 (de) | Substituierte pyrazinonderivate zur verwendung als arzneimittel | |
| WO2008153958A3 (en) | Crystalline forms of (r)-1-{2-[4'- (3-methoxy-propane-1- sulfonyl)-biphenyl-4-yl]-ethyl}-2-methyl-pyrrolidine, and compositions, and methods related thereto | |
| JP2007513968A5 (enExample) | ||
| Giordano et al. | Obstructive sleep apnea in Prader-Willi syndrome: risks and advantages of adenotonsillectomy | |
| Choi et al. | Effects of electrical automatic massage of whole body at bedtime on sleep and fatigue | |
| MX2011008060A (es) | Derivados de amida biciclica para mejorar las respuestas sinapticas glutamatergicas. | |
| NO20090972L (no) | Pyrazolo[1,5-A]pyrimidiner, fremgangsmater, anvendelser og sammensetninger | |
| WO2007061741A3 (en) | Modulators of the h3 receptor useful for the treatment of disorders related thereto | |
| DE602007007206D1 (de) | Substituierte pyrazinonderivate zur verwendung als arzneimittel | |
| JP2008507550A5 (enExample) | ||
| Chow | Sleep in Parkinson's Disease | |
| Yerram et al. | Sleep Issues in Motor Neuron Diseases | |
| EA048116B1 (ru) | Способы и композиции для лечения синдрома обструктивного апноэ, возникающего во сне | |
| Rosenberg | What have we learned from recent clinical trials in AD? |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| HH | Correction or change in general |